BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile

 

BioNumerik Pharmaceuticals, Inc. 

8122 Datapoint Drive

San Antonio  Texas  78229  U.S.A.
Phone: 210-614-1701 Fax: n/a


SEARCH JOBS

View Clinical Trials from BioPharm Insight



Industry
Pharmaceutical






 Company News
BioNumerik Pharmaceuticals, Inc. Appoints Steve Carchedi to Board of Directors 6/14/2012 11:04:13 AM    More...
BioNumerik Pharmaceuticals, Inc. Initiates Treatment of Patients in Global Phase III Clinical Trial of Tavocept(TM) 1/21/2010 9:22:49 AM    More...
BioNumerik Pharmaceuticals, Inc. Observes Evidence of a Survival Increase in Lung Cancer Patients Participating in Tavocept(TM) Clinical Trial 7/17/2008 6:25:19 AM    More...
BioNumerik Pharmaceuticals, Inc. and ASKA Pharmaceutical Announce Results from Phase III Clinical Trial of Tavocept(TM) 3/18/2008 7:26:03 AM    More...
BioNumerik Pharmaceuticals, Inc. Commences Global Phase III Ovarian Cancer Trial on Novel Anticancer Drug Candidate Known as Karenitecin(R) 2/7/2008 7:26:00 AM    More...
The Day In Review: Nuvelo, Inc. (NUVO) Expands Archemix Corporation Deal 8/1/2006 6:11:15 PM    More...
Takeda Pharmaceutical Co. Ltd. (TKDG.DE) And BioNumerik Pharmaceuticals, Inc. Announce Results Of Tavocept(TM) Phase III Trials Focused On Neuropathy Indication - Trials Did Not Meet Their Primary Endpoints 7/31/2006 5:58:22 PM    More...
BioNumerik Pharmaceuticals Sets IPO At 5 Million Shares, $14-$16 10/19/2005 5:11:50 PM    More...
Takeda Pharmaceutical Co. Ltd. (TKDG.DE) Announces Partnership With BioNumerik Pharmaceuticals To Market Tavocept(TM), Phase 3 Chemoprotective Agent, In North America 10/19/2005 5:11:47 PM    More...
BioNumerik Pharmaceuticals Files $86 Million IPO 10/19/2005 5:11:42 PM    More...
12